makereceptor version 3.2.0.2 (OpenEye Scientific Software Inc)
90
Structured Review
OpenEye Scientific Software Inc
makereceptor version 3.2.0.2
Makereceptor Version 3.2.0.2, supplied by OpenEye Scientific Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/makereceptor+3%2E2%2E0%2E2/makereceptor+3+2+0+2/pm34710288-77-6-9
Average 90 stars, based on 1 article reviews
Makereceptor Version 3.2.0.2, supplied by OpenEye Scientific Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/makereceptor+3%2E2%2E0%2E2/makereceptor+3+2+0+2/pm34710288-77-6-9
Average 90 stars, based on 1 article reviews
makereceptor version 3.2.0.2 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Generated:Article Title: Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole–Indole Conjugates as Anticancer CDK Inhibitors Article Snippet: The GUI module “MakeReceptor 3.2.0.2” from the “OEDocking 3.2.0.2” program in Article Title: Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2/5-LOX inhibitors. Article Snippet: The current therapeutic demand focuses more on the discovery of safer NSAIDs rather than exploring more potent alternatives.. The dual COX-2/5-LOX inhibition is a promising strategy for designing compounds with an enhanced efficacy, reduced side-effects and a broader anti-inflammatory spectrum in comparison to classical NSAIDs.. In the present study, a hybridization strategy was adopted to combine the binding features of the nonselective COX inhibitor “sulindac” and the selective COX-2 inhibitor “celecoxib” which show 5-LOX inhibitory activity with that of licofelone and a celecoxib pyridone analogue which show dual COX-2/5-LOX inhibitory activity to design new series of pyrazole sulfonamide derivatives which, by design, should possess dual COX-2/5-LOX inhibitory activity. Article Title: Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole–Indole Conjugates as Anticancer CDK Inhibitors Article Snippet: The GUI module “MakeReceptor 3.2.0.2” from the “OEDocking 3.2.0.2” program in Article Title: Design and synthesis of novel 4-fluorobenzamide-based derivatives as promising anti-inflammatory and analgesic agents with an enhanced gastric tolerability and COX-inhibitory activity. Article Snippet: Responding to the great demand of developing potent NSAIDs with an enhanced safety profile and reasonable selectivity, in the present study novel 4-fluorobenzamide derivatives were synthesized and screened for their anti-inflammatory and analgesic activities using carrageenan-induced rat paw edema method and acetic acidinduced abdominal writhing in mice, respectively.. All the new target compounds except the carbamothioylhydrazine series (5a-d), and the 4-fluorophenyl thiadiazolo derivative 6b showed promising anti-inflammatory activity ranged between 53.43 and 92.36% inhibition of edema (at 3 h) compared to the reference standard indomethacin (65.64%).. All the newly synthesized compounds showed potent analgesic activity ranged between 71 and 100 % writhing protection compared to indomethacin (74.06%). Binding Assay:Article Title: Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole–Indole Conjugates as Anticancer CDK Inhibitors Article Snippet: The GUI module “MakeReceptor 3.2.0.2” from the “OEDocking 3.2.0.2” program in Article Title: Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2/5-LOX inhibitors. Article Snippet: The current therapeutic demand focuses more on the discovery of safer NSAIDs rather than exploring more potent alternatives.. The dual COX-2/5-LOX inhibition is a promising strategy for designing compounds with an enhanced efficacy, reduced side-effects and a broader anti-inflammatory spectrum in comparison to classical NSAIDs.. In the present study, a hybridization strategy was adopted to combine the binding features of the nonselective COX inhibitor “sulindac” and the selective COX-2 inhibitor “celecoxib” which show 5-LOX inhibitory activity with that of licofelone and a celecoxib pyridone analogue which show dual COX-2/5-LOX inhibitory activity to design new series of pyrazole sulfonamide derivatives which, by design, should possess dual COX-2/5-LOX inhibitory activity. Article Title: Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole–Indole Conjugates as Anticancer CDK Inhibitors Article Snippet: The GUI module “MakeReceptor 3.2.0.2” from the “OEDocking 3.2.0.2” program in Article Title: Design and synthesis of novel 4-fluorobenzamide-based derivatives as promising anti-inflammatory and analgesic agents with an enhanced gastric tolerability and COX-inhibitory activity. Article Snippet: Responding to the great demand of developing potent NSAIDs with an enhanced safety profile and reasonable selectivity, in the present study novel 4-fluorobenzamide derivatives were synthesized and screened for their anti-inflammatory and analgesic activities using carrageenan-induced rat paw edema method and acetic acidinduced abdominal writhing in mice, respectively.. All the new target compounds except the carbamothioylhydrazine series (5a-d), and the 4-fluorophenyl thiadiazolo derivative 6b showed promising anti-inflammatory activity ranged between 53.43 and 92.36% inhibition of edema (at 3 h) compared to the reference standard indomethacin (65.64%).. All the newly synthesized compounds showed potent analgesic activity ranged between 71 and 100 % writhing protection compared to indomethacin (74.06%). |